CTKB vs NTRA

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 0. 5% for Cytek Biosciences, Inc. (CTKB). Analysts rate Cytek Biosciences, Inc. (CTKB) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +114. 4%, compared to -75. 4% for Cytek Biosciences, Inc. (CTKB). Over 10 years, the gap is even starker: NTRA returned +1835% versus CTKB's -75. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Natera, Inc.

(NTRA) is the lower-risk stock at 1. 17β versus Cytek Biosciences, Inc. 's 1. 66β — meaning CTKB is approximately 42% more volatile than NTRA relative to the S&P 500. On balance sheet safety, Cytek Biosciences, Inc. (CTKB) carries a lower debt/equity ratio of 7% versus 13% for Natera, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus 0. 5% for Cytek Biosciences, Inc. (CTKB). On earnings-per-share growth, the picture is similar: Natera, Inc. grew EPS 0. 7% year-over-year, compared to -1028. 0% for Cytek Biosciences, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Natera, Inc.

(NTRA) is the more profitable company, earning -9. 0% net margin versus -33. 0% for Cytek Biosciences, Inc. — meaning it keeps -9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NTRA leads at -13. 4% versus -20. 0% for CTKB. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Natera, Inc.

(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), +1835% 10Y return). Cytek Biosciences, Inc. (CTKB) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +1835%, CTKB: -75. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTKB is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.